Clinical Trials at Concorde Gastroenterology
- Posted on: Mar 30 2015
Designed to add to the existing medical knowledge related to the diagnosis, treatment, and prevention of diseases or conditions, clinical trials offer hope to many and also help researchers find better treatment options for other patients in the future. Located in mid-town Manhattan, the Clinical Research Division of Concorde Medical group has extensive experience in orchestrating a wide range of clinical trials at its Kips Bay Office. Working within Concorde’s multi-specialty practice, the Research Division provides its patients with access to early breakthroughs in medical treatments, technologies, as well as pharmaceuticals.
Currently at Concorde Gastroenterology we are working on the following clinical trials:
This randomized, multi-center, double-blind study is designed to compare the safety and efficacy of vancomycin versus cadazolid in subjects who are suffering from Clostridium difficile-associated diarrhea (CDAD). We are looking for female or male patients who are older than 18 years of age, and have been diagnosed with mild-moderate or severe CDAD (first occurrence or first recurrence within 3 months) with diarrhea, and test positive for C. difficile on a stool sample. Click here to read more information on the eligibility requirements of this study.
For patients with moderate to severe active ulcerative colitis, this double blind, phase III, placebo controlled study of the safety and efficacy of etrolizumab during induction and maintenance. In order to be eligible, patients must be 18 and over and have been diagnosed with Ulcerative Colitis at least 6 months prior to entry into the study. Patients must have a resistance, or be intolerant, to one or two (no more than two allowed) TNF-inhibitors such as Golimumab, Infliximab, and Adalimumab within the previous 5 years. Overall this study lasts 66 weeks in total, and the option to enter into the long-term extension study depending on response to treatment is available. Click here to read more information on the eligibility requirements of this study.
AbbVie Legacy Registry Study: Ulcerative Colitis
This registry study evaluates the long-term safety of HUMIRA in moderately to severely active Ulcerative Colitis adult patients who are 18 years of age and over. To be considered to the reference group, patients must be prescribed and treated with IMM (azathioprine (AZA) or 6-mercaptopurine (6-MP)) with no concurrent biologic use. Click here to read more information on the eligibility requirements of this study.
Hepatitis C: Beckman Coulter
For HCV-infected individuals undergoing antiviral therapy, this observational study evaluates the Hepatitis C: Beckman Coulter DxN HCV viral load assay. In order to participate, patients must have Hepatitis C genotypes 1, 2, and 3 and be over the age of 18. Click here to read more information on the eligibility requirements of this clinical trial.
Menarini IBS-D in Women
For FEMALE patients with severe irritable bowel syndrome with diarrhea, this placebo-controlled, randomized, double blind, parallel-group Phase III study is held over a course of 52 weeks and is re-randomized at week 25 to evaluate the safety and effectiveness of 10MG one a day oral Ibodutant (a tachykinin NK2 receptor antagonist). Patients must be over the age of 18, and is required to keep a daily phone diary during the duration of this study. Click here to read more information on the eligibility requirements of this clinical trial.
In addition, we are currently working on the following clinical trials:
- Crohn’s Disease
- Hepatitis B blood collection study
New Clinical trials coming soon:
- Fecal Microbiota Transplantation (FMT)
Interested? If you would like to find out more information about our clinical trials, or if you fit the eligibility criteria listed and are interested in participating, click here to sign up for clinical trials. You may also contact us here if you have any questions, or you can contact our Clinical Research Coordinator:
Posted in: Uncategorized